IONIS GCCRRx

Drug Profile

IONIS GCCRRx

Alternative Names: IONIS-GCCRRx; ISIS-426115; ISIS-GCCR-RX; ISIS-GCCRRx

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antihyperglycaemics; Antisense oligonucleotides
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • No development reported Cushing syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cushing's syndrome(In volunteers) in USA (SC)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 01 May 2015 ISIS Pharmaceuticals completes a phase-II clinical trial in Type-2 diabetes mellitus (Adjunctive treatment) in Canada, Romania and South Africa (SC) (NCT01968265)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top